Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study

AIMS: Capmatinib, a mesenchymal–epithelial transition factor tyrosine kinase inhibitor, is metabolized by cytochrome P450 (CYP) 3A4 and aldehyde oxidase. In individuals with hepatic impairment, alterations in hepatobiliary excretion and metabolism could lead to higher capmatinib exposure. We compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xinhui, Cui, Xiaoming, Pognan, Nathalie, Quinlan, Michelle, Kapoor, Shruti, Rahmanzadeh, Gholamreza, Giovannini, Monica, Marbury, Thomas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291822/
https://www.ncbi.nlm.nih.gov/pubmed/34046915
http://dx.doi.org/10.1111/bcp.14929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291822/
https://www.ncbi.nlm.nih.gov/pubmed/34046915
http://dx.doi.org/10.1111/bcp.14929

Ejemplares similares